Advanced glycation end products  (Synonyms: AGEs)

Advanced glycation end products (AGEs) are a series of stable compounds generated through non-enzymatic reactions between reducing sugars and proteins, lipids, or nucleic acids. Advanced glycation end products are often used as targets to evaluate the inhibitory effects of anti-glycation compounds. Advanced glycation end products can be applied to research on diabetes, cardiovascular and cerebrovascular diseases, inflammation, aging, and other conditions^{[1][2][3][4][5][6]}.

Advanced glycation end products enhance tumorigenicity, invasion, and migration of triple-negative breast cancer cells by upregulating MMP-9 expression via ERK and NF-κB pathway activation^[1].

Advanced glycation end products induce dysfunction and damage in human aortic endothelial cells via activation of MAPK, NF-κB, and AP-1 signaling^[2].
Advanced glycation end products alter gut microbiota composition, induce intestinal epithelial cell damage and gut barrier dysfunction, and drive systemic inflammation and multiorgan injury^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Advanced glycation end products (oral; daily; 4 weeks) induces systemic ER stress in major metabolic tissues of normal mice^[2].
Advanced glycation end products induces cardiac fibrosis in mice by increasing collagen deposits, inducing diastolic dysfunction, and promoting fibroblast-to-myofibroblast differentiation^[2].
Advanced glycation end products promote alcohol-induced brain inflammation, apoptosis, and neuronal damage via RAGE and MAPK pathway activation^[3].
Advanced glycation end products (high-AGEs diet) delays wound healing in mice by promoting persistent inflammatory cell infiltration and fibrous scar formation^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Liquid

Light yellow to yellow

[Advanced glycation end products]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Twarda-Clapa A, et al. Advanced Glycation End-Products (AGEs): Formation, Chemistry, Classification, Receptors, and Diseases Related to AGEs. Cells. 2022 Apr 12;11(8):1312.

  [2]. Kosmopoulos M, et al. Impact of advanced glycation end products (AGEs) signaling in coronary artery disease. Biochim Biophys Acta Mol Basis Dis. 2019;1865(3):611-619.

  [3]. Rungratanawanich W, et al. Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury. Exp Mol Med. 2021;53(2):168-188.

  [4]. Singh R, et al. Advanced glycation end-products: a review. Diabetologia. 2001;44(2):129-146.

  [5]. Haque E, et al. Advanced glycation end products (AGEs), protein aggregation and their cross talk: new insight in tumorigenesis. Glycobiology. 2019 Dec 12;30(1):49-57.

  [6]. Ilea A, et al. Advanced glycation end products (AGEs) in oral pathology. Arch Oral Biol. 2018;93:22-30.